file copy

09/744,603

FULL ESTIMATED COST 148.26 148.47

FILE 'CAPLUS' ENTERED AT 18:34:56 ON 04 NOV 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 4 Nov 2002 VOL 137 ISS 19
FILE LAST UPDATED: 3 Nov 2002 (20021103/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

=> s l15
L16 2 L15

=> d l16 1-2 ibib abs hitstr

L16 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1999:640847 CAPLUS
DOCUMENT NUMBER: 131:257572
TITLE: Preparation of benzoxazinones and -thiazinones as serine protease inhibitors
INVENTOR(S): Berryman, Kent Alan; Downing, Dennis Michael; Dudley, Danette Andrea; Edmunds, Jeremy John; Narasimhan, Lakshmi Sourirajan; Rapundalo, Stephen Taras
PATENT ASSIGNEE(S): Warner-Lambert Company, USA
SOURCE: PCT Int. Appl., 175 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9950257	A1	19991007	WO 1998-US26708	19981215
W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HR, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2319551	AA	19991007	CA 1998-2319551	19981215
AU 9919183	A1	19991018	AU 1999-19183	19981215

BR 9815784	A	20001121	BR 1998-15784		19981215
EP 1068191	A1	20010117	EP 1998-963965		19981215
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
JP 2002509925	T2	20020402	JP 2000-541161		19981215
ZA 9902445	A	19991001	ZA 1999-2445		19990330
NO 2000004698	A	20000920	NO 2000-4698		20000920
PRIORITY APPLN. INFO.:			US 1998-80142P	P	19980331
			WO 1998-US26708	W	19981215

OTHER SOURCE(S): MARPAT 131:257572

GI



I

AB Title compds. [I; R1 = cycloalkyl(alkyl), heterocyclyl(alkyl), aryl(alkyl), etc.; R2 = H or alkyl; R3R4 = (un)substituted CH:CHCH:CH, -N:CHCH:CH, -CH:NCH:CH, etc.; X = O, S, NH; Z = Z2Z3R5; R5 = H, (un)substituted (heteroatom-interrupted) alkyl or -cycloalkyl(alkyl); Z1 = O, SO0-2, OCH2, SCH2, etc.;Z2 = bond or (heteroatom-interrupted) (cyclo)alkylene; Z3 = bond, (un)substituted heterocyclylene, -arylene] were prepd. Thus, 4-(MeO)C6H4CH2CO2Me was .alpha.-brominated and the product etherified by 2-(O2N)C6H4OH to give, after reductive cyclization, I [R1 = C6H4(OMe)-4, R2 = H, R3R4 = CH:CHCH:CH, X = Z1 = O](II; Z = NH) which was N-alkylated by Br(CH2)Br and the product aminated by cis-2,6-dimethylpiperidine to give II [Z =N(CH2)5R5, R5 = cis-2,6-dimethyl-1-piperidinyl]. Data for biol. activity of I were given.

IT **244620-11-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of benzoxazinones and -thiazinones as serine protease inhibitors)

RN 244620-11-9 CAPLUS

CN Guanidine, [3-(2,3-dihydro-3-oxo-2-phenyl-4H-1,4-benzoxazin-4-yl)propyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1963:435587 CAPLUS

L5 STR



G1 O,N

G2 CH2,O,S,N

G3 C,Cy

G4 H,O

Structure attributes must be viewed using STN Express query preparation.

```
=> s l5
SAMPLE SEARCH INITIATED 18:26:28 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      0 TO ITERATE

100.0% PROCESSED       0 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE   **COMPLETE**
                        BATCH    **COMPLETE**
PROJECTED ITERATIONS:             0 TO         0
PROJECTED ANSWERS:                0 TO         0

L6            0 SEA SSS SAM L5

=>
Uploading 924709c.str

L7      STRUCTURE UPLOADED

=> d l7
L7 HAS NO ANSWERS
L7               STR
```

09/744,603



G1 O,N

G2 CH2,O,S,N

G3 C,Cy

G4 H,O

Structure attributes must be viewed using STN Express query preparation.

=>
Uploading 924709b.str

L8 STRUCTURE UPLOADED

=> d l8
L8 HAS NO ANSWERS
L8 STR



G1 O,N

G2 CH2,O,S,N

G3 C,Cy

G4 H,O

Structure attributes must be viewed using STN Express query preparation.

=>
Uploading 924709a.str

L9 STRUCTURE UPLOADED

=> d l9
L9 HAS NO ANSWERS

L9 STR



G1 O,N

G2 CH2,O,S,N

G3 C,Cy

G4 H,O

Structure attributes must be viewed using STN Express query preparation.

```
=> s l8
SAMPLE SEARCH INITIATED 18:30:59 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      0 TO ITERATE

100.0% PROCESSED       0 ITERATIONS                              0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:            0 TO        0
PROJECTED ANSWERS:               0 TO        0

L10           0 SEA SSS SAM L8

=> s l9
SAMPLE SEARCH INITIATED 18:31:04 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      0 TO ITERATE

100.0% PROCESSED       0 ITERATIONS                              0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:            0 TO        0
PROJECTED ANSWERS:               0 TO        0

L11           0 SEA SSS SAM L9

=> s l10
SAMPLE SEARCH INITIATED 18:31:08 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      0 TO ITERATE

100.0% PROCESSED       0 ITERATIONS                              0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
```

PROJECTED ITERATIONS: 0 TO 0
PROJECTED ANSWERS: 0 TO 0

L12 0 SEA SSS SAM L8

=>
Uploading 924709c.str

L13 STRUCTURE UPLOADED

=> d l13
L13 HAS NO ANSWERS
L13 STR



G1 O,N

G2 CH2,O,S,N

G3 C,Cy

G4 H,O

Structure attributes must be viewed using STN Express query preparation.

=> s l13
SAMPLE SEARCH INITIATED 18:34:31 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 4 TO ITERATE

100.0% PROCESSED 4 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 4 TO 200
PROJECTED ANSWERS: 0 TO 0

L14 0 SEA SSS SAM L13

=> s l13 sss full
FULL SEARCH INITIATED 18:34:45 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 46 TO ITERATE

100.0% PROCESSED 46 ITERATIONS 2 ANSWERS
SEARCH TIME: 00.00.02

L15 2 SEA SSS FUL L13

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION

FULL ESTIMATED COST 148.26 148.47

FILE 'CAPLUS' ENTERED AT 18:34:56 ON 04 NOV 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 4 Nov 2002 VOL 137 ISS 19
FILE LAST UPDATED: 3 Nov 2002 (20021103/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

=> s l15
L16 2 L15

=> d l16 1-2 ibib abs hitstr

L16 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1999:640847 CAPLUS
DOCUMENT NUMBER: 131:257572
TITLE: Preparation of benzoxazinones and -thiazinones as serine protease inhibitors
INVENTOR(S): Berryman, Kent Alan; Downing, Dennis Michael; Dudley, Danette Andrea; Edmunds, Jeremy John; Narasimhan, Lakshmi Sourirajan; Rapundalo, Stephen Taras
PATENT ASSIGNEE(S): Warner-Lambert Company, USA
SOURCE: PCT Int. Appl., 175 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9950257	A1	19991007	WO 1998-US26708	19981215
W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HR, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2319551	AA	19991007	CA 1998-2319551	19981215
AU 9919183	A1	19991018	AU 1999-19183	19981215

BR 9815784	A	20001121	BR 1998-15784		19981215
EP 1068191	A1	20010117	EP 1998-963965		19981215
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
JP 2002509925	T2	20020402	JP 2000-541161		19981215
ZA 9902445	A	19991001	ZA 1999-2445		19990330
NO 2000004698	A	20000920	NO 2000-4698		20000920
PRIORITY APPLN. INFO.:			US 1998-80142P	P	19980331
			WO 1998-US26708	W	19981215

OTHER SOURCE(S): MARPAT 131:257572
GI



I

AB Title compds. [I; R1 = cycloalkyl(alkyl), heterocyclyl(alkyl), aryl(alkyl), etc.; R2 = H or alkyl; R3R4 = (un)substituted CH:CHCH:CH, -N:CHCH:CH, -CH:NCH:CH, etc.; X = O, S, NH; Z = Z2Z3R5; R5 = H, (un)substituted (heteroatom-interrupted) alkyl or -cycloalkyl(alkyl); Z1 = O, SO0-2, OCH2, SCH2, etc.;Z2 = bond or (heteroatom-interrupted) (cyclo)alkylene; Z3 = bond, (un)substituted heterocyclylene, -arylene] were prepd. Thus, 4-(MeO)C6H4CH2CO2Me was .alpha.-brominated and the product etherified by 2-(O2N)C6H4OH to give, after reductive cyclization, I [R1 = C6H4(OMe)-4, R2 = H, R3R4 = CH:CHCH:CH, X = Z1 = O](II; Z = NH) which was N-alkylated by Br(CH2)Br and the product aminated by cis-2,6-dimethylpiperidine to give II [Z =N(CH2)5R5, R5 = cis-2,6-dimethyl-1-piperidinyl]. Data for biol. activity of I were given.

IT **244620-11-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of benzoxazinones and -thiazinones as serine protease inhibitors)

RN 244620-11-9 CAPLUS

CN Guanidine, [3-(2,3-dihydro-3-oxo-2-phenyl-4H-1,4-benzoxazin-4-yl)propyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1963:435587 CAPLUS

09/744,603

DOCUMENT NUMBER: 59:35587
ORIGINAL REFERENCE NO.: 59:6389e-h,6390a-h,6391a
TITLE: Development of psychotropic substances. III. Diphenylamine derivatives with pyridyl and guanidyl side chains
AUTHOR(S): Thiel, M.; Stach, K.
CORPORATE SOURCE: Firma C. F. Boehringer Soehne G.m.b.H., Mannheim-Waldhof, Germany
SOURCE: Monatsh. (1962), 93, 1080-9
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
GI For diagram(s), see printed CA Issue.
AB cf. CA 58, 5679a. The syntheses of aminopyridyl and guanidyl derivs. of carbazole, phenothiazine, phenoxazine, and iminodibenzyl are reported. 3-(9-Carbazolyl)propionic acid (I) (100 g.) in 300 cc. CHCl3 refluxed 3 hrs. with 35 cc. SOCl2 and evapd. yielded 102 g. chloride (II) of I, m. 127-30.degree.. 3-(10-Phenothiazinyl)propionic acid (III) in 50 cc. CHCl3 treated dropwise with stirring with 4.6 cc. (COCl)2 in 50 cc. CHCl3, refluxed 3 hrs., and evapd. yielded 12.7 g. chloride (IV) of III, m. 120-2.degree. (Et2O). 5-(2-Cyanoethyl)iminodibenzyl (V) (26 g.), 8.4 g. NaOH, 220 cc. MeOH, and 30 cc. H2O refluxed 24 hrs., dild. with 1.5 l. H2O, filtered, adjusted (2N HCl) to pH 3, and filtered off gave 21 g. CO2H analog (VI) of V, m. 148-9.degree.. VI (8.7 g.) and 7.8 g. SOCl2 in 175 cc. CH2Cl2 refluxed 3 hrs. gave 9 g. chloride (VII) of 3-(10,11-dihydro-5H-dibenzo[b,e]-5-azepinyl)propionic acid (VIII), slowly crystg. oil. The appropriate aminopyridine (0.1 mole), 0.12 mole Et3N, and 75 cc. C6H6 refluxed 1 hr. with a suitable acid chloride and dild. with H2O, and the C6H6 phase worked up gave the corresponding pyridylamide (% yield and m.p. given): 3-pyridylamide of III, 78, 161-2.degree. (MeOH); 4-pyridylamide of III, 68, 164-5.degree. (EtOAc); 2-pyridylamide of III, 41, 144.degree. (C6H6-petr. ether); 2-pyridylamide of I, 60, 177-8.degree. (C6H6); 3-pyridylamide of I, 69, 193-5.degree. (iso-PrOH); 4-pyridylamide of I, 30, 137.degree. (C6H6); 2-pyridylamide of VIII, 45, 144-5.degree. (iso-PrOH-petr. ether). The appropriate pyridylamide (0.1 mole) in 150-200 cc. tetrahydrofuran refluxed 1 hr. with 0.1 mole LiAlH4 in 80 cc. tetrahydrofuran yielded the corresponding substituted propylaminopyridines (IX) (method A). The appropriate 3-substituted propylamine (0.1 mole) and 0.15 mole 4-phenoxypyridine heated 3 hrs. at 180-200.degree., cooled, dissolved in H2O, treated with 2N NaOH, and extd. with CH2Cl2 gave the corresponding IX, (method B). By these methods were prepd. the following compds. which, dissolved in Et2O or dioxane and neutralized with HCl in Et2O or dioxane, gave the HCl salts (method used, % yield, and m.ps. of base and HCl salt given): 2-[3-(9-carbazolyl)propyl amino]pyridine (X), A, 98-9.degree., -; 3-isomer of X, A, 74, 144-5.degree. (MeOH), -; 4-isomer of X, A, 61, 179-80.degree. (C6H6), -; 2-[3-(10-phenothiazinyl)propylamino]pyridine (XI), A, 88, 98-9.degree. (MeOH), 172.degree. (dioxane); 3-isomer of XI, A, 68, 106-7.degree. (EtOAc), 155-6.degree. (EtOH-Et2O); 4-isomer (XII) of XI, A, 60 (B, 65), 166-7.degree. (EtOAc), 190.degree. (dioxane); 4-[3-(10-phenoxazinyl)propylamino]pyridine, B, 61, -; 231-3.degree.(iso-PrOH); 2-[3-(10,11-dihydro-4H-dibenzo[b,e]-5-azepinyl)propyl]pyridine (XIII), A, 49, 74-5.degree. (C6H6-petr. ether); 4-isomer of XIII, B, 55, 160-1.degree. (MeOH), -. 3-(10-Phenothiazinyl)propylamine (XIV) (10 g.), 20 g. 2-chloropyridine, and 6 g. Na2CO3 refluxed 6 hrs., filtered, and evapd., the residue shaken with H2O and Et2O, and the Et2O phase worked up yielded 4.4 g. XI, m. 98-9.degree. (MeOH). NaNH2 (3 g.), 7 g. 2-aminopyridine, and 70 cc. MePh refluxed 2 hrs., treated with 17 g. 3-(10-phenothiazinyl)propyl chloride, refluxed 3 hrs., and decompd. with H2O, the MePh layer evapd., the residue dissolved in Et2O and neutralized with HCl-Et2O, and the ppt. dissolved in a little H2O, treated with solid Na2CO3, and extd. with Et2O gave 3 g. XI, m. 98-9.degree.. A 3-substituted propyl chloride (0.1 mole) and 0.1 mole 2-aminopyridine

heated 3 hrs. with stirring at 120.degree. and cooled yielded the corresponding XV. The appropriate 3-substituted propyl chloride (0.1 mole) and 0.1 mole 4-aminopyridine in 300 cc. EtAc or Et2CO refluxed 16 hrs. with stirring gave the corresponding XV. By these methods were prepd. the following XV (X, position of the NH2 group in the pyridine ring, % yield, and m.p. given): 9-carbazolyl, 2, 41, 125-7.degree. (EtOH-EtOAc); 9-carbazolyl, 4, 53, 268.degree. (EtOH-EtAc); 10-phenothiazinyl, 2, 60, 185-7.degree. (H2O); 10-phenothiazinyl, 4, 67, 197-8.degree. (EtOH-EtOAc); 10-phenoxazinyl, 2, 22, 248-50.degree. (PrOH); 10-phenoxazinyl, 4, 59, 228-30.degree. (EtOH-EtAc); 10,11 dihydro-5H-dibenzo[b,e]-5-azepinyl, 2, 24, 178-9.degree. (MeOH-EtAc); 10,11-dihydro-5H-dibenzo[b,e]-5-azepinyl, 4, 51, 160-1.degree. (MeOH-EtOAc). 4-Dimethylaminopyridine (6 g.), 14 g. 10-(3-chloropropyl)phenothiazine, and 70 cc. EtAc refluxed 24 hrs., cooled, and filtered off gave 12.4 g. 1-[3-(10-phenothiazinyl)propyl]-4-dimethylaminopyridinium chloride, 0.5 H2O, m. 171-2.degree.. 9-(3-Aminopropyl)carbazole (20 g.) and 9 g. EtNCS in 100 cc. C6H6 refluxed 8 hrs. and refrigerated yielded 18 g. N-[3-(9-carbazolyl)propyl]-N'-ethylthiourea (XVI), m. 82-4.degree. (MeOH). XVI (9 g.) in 23 cc. EtOH refluxed 2 hrs. with 3.4 g. EtBr and evapd., and the residue repptd. from EtOH with EtOAc yielded 11.4 g. S-ethyl-N-[3-(9-carbazolyl)propyl]-N'-ethylisothiourea-HBr (XVII.HBr), m. 106-8.degree.. 9 (3-Aminopropyl)carbazole (10 g.) and 5.7 g. BuNCS gave similarly 17 g. N'-Bu analog (XVIII) of XVI, m. 107-8.degree.. XVIII(15 g.)in 50 cc. MeOH refluxed 4 hrs. with stirring with 4.6 cc. Me2SO4 and evapd., the residue shaken with 2N NaOH and CHCl3, and the residue (XVIIIa) from the CHCl3 phase dissolved in Et2O and treated with (CO2H)2 in Et2O gave 17 g. oxalate of the N'-Bu analog of XVII, m. 155-7.degree. (EtOH). The appropriate 3-substituted propylamine (0.1 mole) and 0.2 mole guanidine rhodanide heated 2 hrs. at 170.degree., poured hot into boiling 20% aq. K2CO3, filtered off, the residue dissolved in dil. HCl, filtered, treated with aq. NaOAc, and again filtered off gave the corresponding X(CH2)3NRC(:NR')NHR'' (XIX) acetate, which suspended in a little EtOH and treated with the calcd. amt. alc. HCl gave the XIX.HCl (method A). 3-(10-Phenothiazinyl)propylamine (10 g.) and 10 g. [EtSC(NH2)2]Cl (XX) in 100 cc. MeOH refluxed until the MeSH evolution ceased, evapd., and the residue dissolved in H2O and pptd. with aq. NaOAc gave 9.5g. XIX.AcOH (R, R', R'' = H), m. 255-60.degree. (MeOH) (method B), also obtained in 62% yield by method A and isolated as the HCl salt, m. 156-7.degree. (EtOH-Et2O). XVIIIa (11 g.) stirred with 2N NaOH and extd. with CHCl3, the residue from the ext. dissolved in 100 cc. EtOH, neutralized with alc. HCl, satd. with NH3, heated 8 hrs. at 100.degree. in an autoclave and evapd., the residue shaken with H2O and Et2O, and the aq. phase evapd. yielded 1 g. 9-(3-butylguanidylpropyl)carbazole-HCl, m. 156-8.degree. (iso-PrOH) (method C). XIV (17.2 g.) and 24 g. 2-methylthio-.DELTA.2-imidazoline-HI in 250 cc. abs. EtOH refluxed 6 hrs. (MESH evolved), concd., and shaken with H2O and Et2O, the aq. and oily layers basified and extd. with C6H6, and the residue from the ext. triturated with EtOAc yielded 16.5 g. 2-[3-(10-phenothiazinyl)propylamino]-.DELTA.2-imidazoline, m. 118-20.degree.. 10-(3-Methylaminopropyl)phenothiazine (XXI) (23 g.) and 16.1 g. XX in 70 cc. EtOH refluxed 6 hrs. and evapd., the residue dissolved in H2O, basified, and extd. with C6H6, and the residue from the ext. neutralized with alc. HCl and dild. to turbidity with EtOAc gave 8 g. N1-methyl-N1-[3-(10-phenothiazinyl)propyl]guanidine-HCl, m. 135-7.degree. (EtOH-EtOAc). Similarly were prepd. the following XIX (X, R, R', R'', method used, % yield, salt-forming acid, and m.p. of salt given): 9-carbazolyl, H, H, H, A, 58, HCl, 129-31.degree. (EtOH-EtOAc); 9-carbazolyl, H, H, NH3, B, 52, HBr, 160-1.degree. (PrOH); 9-carbazolyl, H, Et, NH2, C, 44, HBr, 160.degree. (MeOH-EtOAc); 10-phenoxazinyl, H, H, H, A, 36, HCl, 136-8.degree. (H2O); 10-phenothiazinyl, H, H, NH2, B, 53, HBr, 122-4.degree. (iso-PrOH); 10,11-dihydro-5H-dibenzo[b,e]-5-azepinyl, H, H, H, A, 72, AcOH, 133-5.degree. (H2O); 10,11-dihydro-5H-dibenzo[b,e]-5-

azepinyl, H, H, NH_2, B, 50, HBr, 163-4.degree. (PrOH).
10-(3-Chloropropyl)phenothiazine (27 g.) in 300 cc. MeOH satd. with $MeNH_2$, heated 5 hrs. at 100.degree. in an autoclave, and evapd., and the residue treated with NaOH and extd. with Et_2O yielded 23 g. XXI, b0.2 180-5.degree..

IT **98111-67-2**, Guanidine, (3-phenoxazin-10-ylpropyl)-, hydrochloride (prepn. of)

RN 98111-67-2 CAPLUS

CN Guanidine, (3-phenoxazin-10-ylpropyl)-, hydrochloride (7CI) (CA INDEX NAME)



●x HCl

=>